Christos Argyropoulos,
Assistant Professor, Division of Nephrology,
University of New Mexico
Dr Christos Argyropoulos earned his MD from the Medical School, University of Patras, Greece in 1997. He awarded his PhD from the same institution for his work on the identification of the oncogene ets-2 as a transcriptional repressor in naïve T cells using a combination of statistical bioinformatics and wet lab techniques. He completed his clinical Internal Medicine residency at the University of Cincinnati and his clinical nephrology and transplant fellowship at the University of Pittsburgh Medical Center in 2009. He joined the University of Pittsburgh as a postdoctoral research scholar in 2009 where he remained until late 2010. During this period he worked on a number of patient-oriented research projects in Chronic Kidney Disease, but also basic and translational research on kidney morphogenesis, the epithelial sodium channel and microRNAs. Between 2011-2014 he supported the ex-US Medical Affairs operations of Abbot Laboratories and AbbVie in Renal Care. He joined the faculty of the University of New Mexico in May 2014 as an Assistant Professor of Nephrology. Dr Argyropoulos research work leverages Bayesian statistical techniques for the solution of research questions in epidemiology, clinical trials and translation of clinical observations to basic science insights and re-translation of the latter to the bedside. He is currently exploring the role of microRNAs as diagnostics and therapeutics in chronic kidney disease and diabetes. Dr Argyropoulos has received a number of awards and distinctions including the Renal Discoveries Grant from Baxter Healthcare (2008), the Frank Brans Teaching Award (Univeristy and Pittsburgh) the “try” program Abbott Laboratories(2012) and AbbVie’s Specialty Pharmaceutical Division Forum Expo (2014).
Urinary microRNAs in Early Diabetic Kidney Disease: Measurements, Context and Clinical Prediction
Thursday, 15 January 2015 at 16:00
Add to Calendar ▼2015-01-15 16:00:002015-01-15 17:00:00Europe/LondonUrinary microRNAs in Early Diabetic Kidney Disease: Measurements, Context and Clinical PredictionPrognostic, Predictive, and POC: Biomarkers from Research to Clinic in San Diego, California, USASan Diego, California, USASELECTBIOenquiries@selectbiosciences.com
Very little information currently exists about urinary microRNA and their association with development of clinical kidney disease in patients with diabetes. This knowledge gap persists despite microRNA’s involvement in the regulation of pathways that are of biological significance in the development of diabetic kidney disease. Filling in the gap may pave the way to novel therapeutics since the current therapeutic paradigm of blockers of the renin-angiotensin-aldosterone axis, reduces risk of renal disease by 30% and many of the large scale trials ran in the last five years fail to translate to novel therapies. In this talk I will describe the associations of urinary microRNA signatures associated with the future development of early diabetic kidney disease (diagnosed with the current gold standard of a positive microalbumin test in the urine). A number of microRNAs manifest differential expression changes in the urine of patients who eventually developed kidney damage v.s. those who did not, while some of these changes were even gender specific. A formal statistical rigorous algorithm for the evidence synthesis of microRNA expression changes and their mRNA targets to provide a context for the understanding of these associations will be presented. In spite of the strength of the associations only a small number of those are plausibly predictive of the future development of kidney damage. Our group thus developed, and internally validated a microRNA “context aware” signature for the early diagnosis of diabetic kidney disease. The implications for clinical practice and drug discovery will also be discussed.
Add to Calendar ▼2015-01-15 00:00:002015-01-16 00:00:00Europe/LondonPrognostic, Predictive, and POC: Biomarkers from Research to ClinicPrognostic, Predictive, and POC: Biomarkers from Research to Clinic in San Diego, California, USASan Diego, California, USASELECTBIOenquiries@selectbiosciences.com